We are pleased to announce a strategic collaboration with Keltic Pharma Therapeutics to expand its peptide discovery capabilities. The partnership will give BioAscent customers access to Keltic’s proprietary PEPSMOL© platform, a breakthrough technology that translates cyclic peptide hits into potent, selective small molecules.

The collaboration enhances our existing peptide service offering by combining high-quality screening and medicinal chemistry expertise with Keltic’s innovative peptide-to-small-molecule approach. Together, we will accelerate discovery for challenging drug targets - particularly G-protein coupled receptors (GPCRs), which have historically proven difficult to address with conventional methods.

“At BioAscent, we are committed to providing our customers with the most advanced tools and expertise to drive their discovery programmes forward,” said Dr Mike Piper, Chief Commercial Officer at BioAscent. “By integrating the PEPSMOL platform into our integrated drug discovery services, we can offer a powerful new route to high-quality leads for targets that were once considered intractable.”

Keltic’s PEPSMOL© platform enables the creation of vast, precisely controlled cyclic peptide libraries. Hits from these libraries can then be rapidly refined into drug-like small molecules with improved pharmacokinetics, opening new opportunities across multiple therapeutic areas.

“This collaboration with BioAscent is an important milestone in making our platform broadly available to the biotech and pharma community,” said Andrew Tobin, CEO, Keltic Pharma. “By working with BioAscent’s experienced team and established customer base, we can help unlock new drug discovery opportunities and bring forward more effective treatments, faster.”

The partnership reflects a shared commitment to innovation and customer impact, ensuring BioAscent’s customers have access to a best-in-class, integrated solution for peptide-driven drug discovery.